NantKwest, Inc. (NASDAQ:NK) CFO Sonja Nelson sold 16,364 shares of the company’s stock in a transaction that occurred on Tuesday, January 12th. The shares were sold at an average price of $15.00, for a total transaction of $245,460.00. Following the transaction, the chief financial officer now directly owns 31,774 shares in the company, valued at approximately $476,610. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Sonja Nelson also recently made the following trade(s):
- On Monday, January 4th, Sonja Nelson sold 39,271 shares of NantKwest stock. The stock was sold at an average price of $13.62, for a total transaction of $534,871.02.
Shares of NK stock opened at $14.78 on Thursday. The company’s fifty day simple moving average is $12.33 and its 200-day simple moving average is $10.05. NantKwest, Inc. has a 52 week low of $2.52 and a 52 week high of $19.37. The company has a market cap of $1.61 billion, a PE ratio of -20.82 and a beta of 2.52.
Several hedge funds have recently modified their holdings of the company. Strs Ohio raised its stake in shares of NantKwest by 21.0% in the 3rd quarter. Strs Ohio now owns 7,500 shares of the biotechnology company’s stock valued at $52,000 after acquiring an additional 1,300 shares during the period. Schonfeld Strategic Advisors LLC grew its holdings in NantKwest by 163.1% during the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 125,800 shares of the biotechnology company’s stock valued at $873,000 after purchasing an additional 77,982 shares in the last quarter. California State Teachers Retirement System grew its holdings in NantKwest by 10.0% during the 3rd quarter. California State Teachers Retirement System now owns 47,701 shares of the biotechnology company’s stock valued at $331,000 after purchasing an additional 4,345 shares in the last quarter. Point72 Hong Kong Ltd acquired a new stake in NantKwest during the 3rd quarter valued at $48,000. Finally, Cubist Systematic Strategies LLC acquired a new stake in NantKwest during the 3rd quarter valued at $132,000. 9.22% of the stock is currently owned by institutional investors and hedge funds.
NantKwest, Inc, a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and Nant cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells.
Recommended Story: The benefits and drawbacks of dollar cost averaging
Receive News & Ratings for NantKwest Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantKwest and related companies with MarketBeat.com's FREE daily email newsletter.